In yesterday’s Wall Street session, Astrazeneca plc ADR (NASDAQ:AZN) shares traded at $66.81, down -0.28% from the previous session.
AZN stock price is now 1.65% away from the 50-day moving average and -0.06% away from the 200-day moving average. The market capitalization of the company currently stands at $207.14B.
On January 23, 2024, Morgan Stanley recently initiated its ‘Overweight’ rating on the stock quoting a target price of $85, while ‘UBS’ rates the stock as ‘Sell’
A total of 0.03% of the company’s stock is owned by insiders.
During the past 12 months, Astrazeneca plc ADR has had a low of $60.47 and a high of $76.56. As of last week, the company has a debt-to-equity ratio of 0.73, a current ratio of 0.82, and a quick ratio of 0.64. According to the stock market information, the enterprise value for the company is $230.44B, which is based on a 35.01 price-to-earnings ratio, a 2.67 price-to-earnings-growth ratio, and a beta of 0.53. The fifty day moving average price for AZN is $65.69 and a two-hundred day moving average price translates $66.56 for the stock.
The latest earnings results from Astrazeneca plc ADR (NASDAQ: AZN) was released for Dec, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $0.72, missing analysts’ expectations of $0.79 by -0.07. This compares to $0.29 EPS in the same period last year. The net profit margin was 13.00% and return on equity was 15.63% for AZN. The company reported revenue of $12.02 billion for the quarter, compared to $11.21 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.28 percent. For the current quarter, analysts expect AZN to generate $12.01B in revenue.
Astrazeneca plc ADR(AZN) Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
